New strategy aims to tame treatment side effects in lung cancer patients
NCT ID NCT07469488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a special care plan to help Chinese patients with advanced EGFR-mutated lung cancer who are taking the drug amivantamab. The plan focuses on preventing common side effects like blood clots, skin rashes, and infusion reactions. About 122 adults will join to see if this approach improves their quality of life and reduces treatment-related problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFUSION REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail